883 related articles for article (PubMed ID: 10541552)
1. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
[TBL] [Abstract][Full Text] [Related]
2. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
[TBL] [Abstract][Full Text] [Related]
3. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development.
Eischen CM; Alt JR; Wang P
Oncogene; 2004 Nov; 23(55):8931-40. PubMed ID: 15467748
[TBL] [Abstract][Full Text] [Related]
4. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis.
Alt JR; Greiner TC; Cleveland JL; Eischen CM
EMBO J; 2003 Mar; 22(6):1442-50. PubMed ID: 12628936
[TBL] [Abstract][Full Text] [Related]
5. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53.
Schmitt CA; McCurrach ME; de Stanchina E; Wallace-Brodeur RR; Lowe SW
Genes Dev; 1999 Oct; 13(20):2670-7. PubMed ID: 10541553
[TBL] [Abstract][Full Text] [Related]
6. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF.
Jacobs JJ; Scheijen B; Voncken JW; Kieboom K; Berns A; van Lohuizen M
Genes Dev; 1999 Oct; 13(20):2678-90. PubMed ID: 10541554
[TBL] [Abstract][Full Text] [Related]
7. Malignant transformation of Slp65-deficient pre-B cells involves disruption of the Arf-Mdm2-p53 tumor suppressor pathway.
Ta VB; de Bruijn MJ; ter Brugge PJ; van Hamburg JP; Diepstraten HJ; van Loo PF; Kersseboom R; Hendriks RW
Blood; 2010 Feb; 115(7):1385-93. PubMed ID: 20008789
[TBL] [Abstract][Full Text] [Related]
8. p53-independent functions of the p19(ARF) tumor suppressor.
Weber JD; Jeffers JR; Rehg JE; Randle DH; Lozano G; Roussel MF; Sherr CJ; Zambetti GP
Genes Dev; 2000 Sep; 14(18):2358-65. PubMed ID: 10995391
[TBL] [Abstract][Full Text] [Related]
9. Regulatory elements in the immunoglobulin heavy chain gene 3'-enhancers induce c-myc deregulation and lymphomagenesis in murine B cells.
Wang J; Boxer LM
J Biol Chem; 2005 Apr; 280(13):12766-73. PubMed ID: 15687498
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
Meng X; Carlson NR; Dong J; Zhang Y
Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
[TBL] [Abstract][Full Text] [Related]
11. MIF loss impairs Myc-induced lymphomagenesis.
Talos F; Mena P; Fingerle-Rowson G; Moll U; Petrenko O
Cell Death Differ; 2005 Oct; 12(10):1319-28. PubMed ID: 15947793
[TBL] [Abstract][Full Text] [Related]
12. A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis.
Odvody J; Vincent T; Arrate MP; Grieb B; Wang S; Garriga J; Lozano G; Iwakuma T; Haines DS; Eischen CM
Oncogene; 2010 Jun; 29(22):3287-96. PubMed ID: 20305689
[TBL] [Abstract][Full Text] [Related]
13. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
14. p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53.
Lindström MS; Klangby U; Wiman KG
Oncogene; 2001 Apr; 20(17):2171-7. PubMed ID: 11360201
[TBL] [Abstract][Full Text] [Related]
15. Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function.
Kamijo T; van de Kamp E; Chong MJ; Zindy F; Diehl JA; Sherr CJ; McKinnon PJ
Cancer Res; 1999 May; 59(10):2464-9. PubMed ID: 10344759
[TBL] [Abstract][Full Text] [Related]
16. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.
Park SS; Kim JS; Tessarollo L; Owens JD; Peng L; Han SS; Tae Chung S; Torrey TA; Cheung WC; Polakiewicz RD; McNeil N; Ried T; Mushinski JF; Morse HC; Janz S
Cancer Res; 2005 Feb; 65(4):1306-15. PubMed ID: 15735016
[TBL] [Abstract][Full Text] [Related]
17. Tumor spectrum in ARF-deficient mice.
Kamijo T; Bodner S; van de Kamp E; Randle DH; Sherr CJ
Cancer Res; 1999 May; 59(9):2217-22. PubMed ID: 10232611
[TBL] [Abstract][Full Text] [Related]
18. Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells.
Wang P; Lushnikova T; Odvody J; Greiner TC; Jones SN; Eischen CM
Oncogene; 2008 Mar; 27(11):1590-8. PubMed ID: 17828300
[TBL] [Abstract][Full Text] [Related]
19. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2.
Kamijo T; Weber JD; Zambetti G; Zindy F; Roussel MF; Sherr CJ
Proc Natl Acad Sci U S A; 1998 Jul; 95(14):8292-7. PubMed ID: 9653180
[TBL] [Abstract][Full Text] [Related]
20. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
